Want to see HK:2162 full AI Analyst Report?
Keymed Biosciences, Inc. (2162) Income Statement
Keymed Biosciences, Inc. Income Statement
Last quarter (Q2 2026), Keymed Biosciences, Inc.'s total revenue was $608.55M, an increase of 1012.89% from the same quarter last year. In Q2, Keymed Biosciences, Inc.'s net income was $1.20B. See Keymed Biosciences, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 697.77M | $ 428.12M | $ 354.10M | $ 100.06M | $ 110.27M | |
| $ 516.51M | $ 415.92M | $ 317.22M | $ 97.48M | $ 93.07M | |
| $ 1.10B | $ 1.03B | $ 752.02M | $ 641.29M | $ 450.61M | |
| Depreciation and Amortization | $ 98.03M | $ 93.23M | $ 69.16M | $ 36.12M | $ 21.02M |
| $ -486.83M | $ -532.86M | $ -269.77M | $ -259.25M | $ -3.86B | |
| $ -584.85M | $ -618.10M | $ -434.80M | $ -543.81M | $ -3.88B | |
| $ 77.61M | $ 109.45M | $ 78.61M | $ 240.21M | $ -3.52B | |
| $ -507.25M | $ -508.65M | $ -356.19M | $ -303.60M | $ -3.89B | |
| $ -509.11M | $ -515.24M | $ -359.36M | $ -308.12M | $ -3.90B | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.86 | $ -1.97 | $ -1.37 | $ -1.18 | $ -24.24 |
| Diluted EPS | $ -1.86 | $ -1.97 | $ -1.37 | $ -1.18 | $ -24.24 |
| Weighted Average Shares Outstanding | 273.98M | 261.95M | 261.37M | 261.13M | 160.85M |
| Weighted Average Shares Outstanding (Diluted) | 273.98M | 261.95M | 261.37M | 261.13M | 160.85M |
Currency in CNY
